Phase IB study of the FLT3 kinase inhibitor midostaurin with chemotherapy in younger newly diagnosed adult patients with acute myeloid leukemia.

MLA

Stone, R. M., et al. “Phase IB Study of the FLT3 Kinase Inhibitor Midostaurin with Chemotherapy in Younger Newly Diagnosed Adult Patients with Acute Myeloid Leukemia.” Leukemia, vol. 26, no. 9, Sept. 2012, pp. 2061–68. EBSCOhost, https://doi.org/10.1038/leu.2012.115.

APA

Stone, R. M., Fischer, T., Paquette, R., Schiller, G., Schiffer, C. A., Ehninger, G., Cortes, J., Kantarjian, H. M., DeAngelo, D. J., Huntsman-Labed, A., Dutreix, C., del Corral, A., & Giles, F. (2012). Phase IB study of the FLT3 kinase inhibitor midostaurin with chemotherapy in younger newly diagnosed adult patients with acute myeloid leukemia. Leukemia, 26(9), 2061–2068. https://doi.org/10.1038/leu.2012.115

Chicago

Stone, R M, T Fischer, R Paquette, G Schiller, C A Schiffer, G Ehninger, J Cortes, et al. 2012. “Phase IB Study of the FLT3 Kinase Inhibitor Midostaurin with Chemotherapy in Younger Newly Diagnosed Adult Patients with Acute Myeloid Leukemia.” Leukemia 26 (9): 2061–68. doi:10.1038/leu.2012.115.